- The FDA has approved GSK Plc’s (NYSE:GSK) Priorix vaccine to prevent measles, mumps, and rubella (MMR) in those aged one year and above.
- The vaccine can be given in two doses. It may also be administered as a second shot to previously vaccinated individuals with the first dose of another MMR-containing vaccine.
- According to a government study released last month, child vaccination rates in the U.S. fell during the COVID-19 pandemic as many children skipped doctor appointments and states eased vaccine requirements during remote learning.
- “We’re proud to make Priorix available in the U.S. for the first time, adding a choice for providers to help protect patients against these highly-contagious diseases,” GSK Head of U.S. Vaccines Judy Stewart said.
- In recent years, measles outbreaks have occurred globally, with more than 400,000 cases confirmed in 2019.
- Priorix, Priorix Tetra, and chickenpox vaccine Varilrix contributed £260 million to GSK’s vaccine turnover in 2021.
- Price Action: GSK shares are up 1.22% at $43.24 during the premarket session on the last check Monday.
Morgan Stanley Maintains Equal-Weight on Duke Energy, Lowers Price Target to $121
Morgan Stanley analyst Stephen Byrd maintains Duke Energy (NYSE:DUK) with a Equal-Weight and lowers the price target from $123 to $121.
